Biological drug concentration thresholds associated with favorable therapeutic outcomes in Inflammatory Bowel Diseases

Biological drugTreatment Suggested drug concentration thresholds for clinical response/remission (µg/ml)Suggested drug concentration thresholds for mucosal heading (µg/ml)
InfliximabInduction (week 2)

Induction (week 6)

Postinduction (week 14)

Maintenance

≥ 20

≥ 10

≥ 3

≥ 3

≥ 25

N/A

≥ 7

≥ 7

AdalimumabPostinduction (week 14)

Maintenance

≥ 5

≥ 3

≥ 7

≥ 8

Certolizumab pegolPostinduction (week 6)

Maintenance

≥ 32

≥ 15

N/A

N/A

GolimumabPostinduction (week 6)

Maintenance

≥ 2.5

≥ 1

N/A

N/A

Vedolizumab Induction (week 2)

Induction (week 6)

Postinduction (week 14)

Maintenance

≥ 28

≥ 24

≥ 15

≥ 12

N/A

N/A

≥ 17 

≥ 14

UstekinumabPostinduction (week 8)

Maintenance

≥ 3.5

≥ 1

N/A

≥ 4.5

  • 13 Papamichael K et al. Therapeutic drug monitoring in inflammatory bowel disease: for every patient and every drugCurr Opin Gastroenterol. 2019 Apr 9.